Psychedelics and AI promise the next breakthrough treatment for dementia
Spannr - 30-Mar-2023Benefits of psychedelic drugs or AI compounds may outperform clinical drugs with fewer side effects; clinical trials yet to confirm
Join the club for FREE to access the whole archive and other member benefits.
Co-founder at April19 and Salina Health
Richard comes from an AI and machine learning background (undergraduate and D.Phil), with a career in software consulting.
He has applied AI techniques in drug discovery, financial prediction, cognitive modelling. In software, he has wide experience in advising and developing software with agile engineering teams.
Richard’s expertise in AI spans 30 years from his undergrad in AI and Phd in machine learning at the University of Sussex. Richard combines machine learning with a deep knowledge of building and deploying large-scale enterprise software systems. At April19 he leads teams applying AI to discover novel psychedelic compounds.
Visit website: https://www.april19.ai/#richard
See also: April19 - AI-driven psychedelic drug discovery
Details last updated 23-Jun-2023
Benefits of psychedelic drugs or AI compounds may outperform clinical drugs with fewer side effects; clinical trials yet to confirm